Literature DB >> 32016079

Definitive radiation for early stage lung cancer: who is medically inoperable?

Gonzalo Varela1, Nuria M Novoa2.   

Abstract

Entities:  

Year:  2019        PMID： 32016079      PMCID： PMC6976414          DOI： 10.21037/atm.2019.09.49

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  27 in total

1.  Stereotactic Ablative Radiotherapy (SABR) in Patients with Medically Inoperable Peripheral Early Stage Lung Cancer: Outcomes for the First UK SABR Cohort.

Authors:  L Murray; S Ramasamy; J Lilley; M Snee; K Clarke; H B Musunuru; A Needham; R Turner; V Sangha; M Flatley; K Franks
Journal:  Clin Oncol (R Coll Radiol)       Date:  2015-10-21       Impact factor: 4.126

2.  Stereotactic body radiation therapy for early-stage non-small cell lung cancer: Executive Summary of an ASTRO Evidence-Based Guideline.

Authors:  Gregory M M Videtic; Jessica Donington; Meredith Giuliani; John Heinzerling; Tomer Z Karas; Chris R Kelsey; Brian E Lally; Karen Latzka; Simon S Lo; Drew Moghanaki; Benjamin Movsas; Andreas Rimner; Michael Roach; George Rodrigues; Shervin M Shirvani; Charles B Simone; Robert Timmerman; Megan E Daly
Journal:  Pract Radiat Oncol       Date:  2017-06-05

3.  Phase 2 Study of Stereotactic Body Radiation Therapy and Stereotactic Body Proton Therapy for High-Risk, Medically Inoperable, Early-Stage Non-Small Cell Lung Cancer.

Authors:  Chonnipa Nantavithya; Daniel R Gomez; Xiong Wei; Ritsuko Komaki; Zhongxing Liao; Steven H Lin; Melenda Jeter; Quynh-Nhu Nguyen; Heng Li; Xiaodong Zhang; Falk Poenisch; X Ronald Zhu; Peter A Balter; Lei Feng; Noah C Choi; Radhe Mohan; Joe Y Chang
Journal:  Int J Radiat Oncol Biol Phys       Date:  2018-03-02       Impact factor: 7.038

4.  Recalibration of the revised cardiac risk index in lung resection candidates.

Authors:  Alessandro Brunelli; Gonzalo Varela; Michele Salati; Marcelo F Jimenez; Cecilia Pompili; Nuria Novoa; Armando Sabbatini
Journal:  Ann Thorac Surg       Date:  2010-07       Impact factor: 4.330

5.  Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials.

Authors:  Joe Y Chang; Suresh Senan; Marinus A Paul; Reza J Mehran; Alexander V Louie; Peter Balter; Harry J M Groen; Stephen E McRae; Joachim Widder; Lei Feng; Ben E E M van den Borne; Mark F Munsell; Coen Hurkmans; Donald A Berry; Erik van Werkhoven; John J Kresl; Anne-Marie Dingemans; Omar Dawood; Cornelis J A Haasbeek; Larry S Carpenter; Katrien De Jaeger; Ritsuko Komaki; Ben J Slotman; Egbert F Smit; Jack A Roth
Journal:  Lancet Oncol       Date:  2015-05-13       Impact factor: 41.316

6.  Changes in Treatment Patterns and Overall Survival in Patients With Early-Stage Non-Small Cell Lung Cancer in the United States After the Incorporation of Stereotactic Ablative Radiation Therapy: A Population-based Analysis.

Authors:  Waqar Haque; Sean Szeja; Anne Tann; Sarathi Kalra; Bin S Teh
Journal:  Am J Clin Oncol       Date:  2018-03       Impact factor: 2.339

7.  Stereotactic Ablative Radiotherapy as an Alternative to Lobectomy in Patients With Medically Operable Stage I NSCLC: A Retrospective, Multicenter Analysis.

Authors:  Vieri Scotti; Alessio Bruni; Giulio Francolini; Marco Perna; Polina Vasilyeva; Mauro Loi; Gabriele Simontacchi; Domenico Viggiano; Biancaluisa Lanfranchi; Alessandro Gonfiotti; Juljana Topulli; Emanuela Olmetto; Virginia Maragna; Katia Ferrari; Viola Bonti; Camilla Comin; Sara Balduzzi; Roberto D'Amico; Frank Lohr; Luca Voltolini; Lorenzo Livi
Journal:  Clin Lung Cancer       Date:  2018-09-08       Impact factor: 4.785

8.  Physiologic evaluation of the patient with lung cancer being considered for resectional surgery: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.

Authors:  Alessandro Brunelli; Anthony W Kim; Kenneth I Berger; Doreen J Addrizzo-Harris
Journal:  Chest       Date:  2013-05       Impact factor: 9.410

9.  Cardiac radiation dose distribution, cardiac events and mortality in early-stage lung cancer treated with stereotactic body radiation therapy (SBRT).

Authors:  Leonid B Reshko; Noah S Kalman; Geoffrey D Hugo; Elisabeth Weiss
Journal:  J Thorac Dis       Date:  2018-04       Impact factor: 2.895

Review 10.  Which patients benefit most from stereotactic body radiotherapy or surgery in medically operable non-small cell lung cancer? An in-depth look at patient characteristics on both sides of the debate.

Authors:  Gail Wan Ying Chua; Kevin Lee Min Chua
Journal:  Thorac Cancer       Date:  2019-08-06       Impact factor: 3.500
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.